RFA-CK-22-001, Investigation of Monkeypox and Other Zoonotic Diseases in the Democratic Republic of the Congo (DRC) - 2022

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 6U01CK000666-03M001

Grant search

Key facts

  • Disease

    mpox
  • Start & end year

    2022
    2027
  • Known Financial Commitments (USD)

    $100,000
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR DIDINE KABA
  • Research Location

    Congo (DRC)
  • Lead Research Institution

    KINSHASA SCHOOL OF PUBLIC HEALTH
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

  • Mpox Research Priorities

    N/A

  • Mpox Research Sub Priorities

    N/A

Abstract

Project Summary The goals of this project are to improve the scientific understanding and reduce the clinical burden of Monkeypox (MPX) and other zoonotic diseases in Democratic Republic of the Congo (DRC). This should directly support the U.S. CDC mission of strengthening public health surveillance systems globally to prevent the spread of emerging diseases. This project will rely upon the Kinshasa School of Public Health's considerable experience with training public health practitioners, conducting scientific research trials, and supporting the DRC Ministry of Health to accomplish its objectives. The project will be framed around a laboratory-based surveillance system for MPX in DRC to collect accurate case burden data. We will expand upon this framework by evaluating new training methods for health workers, improving geographic data, and assessing new diagnostic platforms when available. We will use our relationships with health systems in highly affected areas to conduct clinical trials of care regimens, vaccines, and anti-viral therapies. We will perform serosurveys in high-risk and survivor populations to better understand transmission risk factors, viral persistence, and sequalae. We will work with key groups in these areas to identify wildlife reservoirs of MPX and collect qualitative data on the attitudes and behaviors of key populations living in these communities. We will work with the government of DRC to improve the ability to respond to outbreaks quickly by preemptively training response workers, developing health promotion networks, and responding to misinformation rapidly. We will share results with national stakeholders and other nations interested in being better prepared for responding to endemic and imported MPX cases.